This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sausville, E. A. Articles by Holland, E. C. Search for Related Content PubMed PubMed Citation Articles by Sausville, E. A. Articles by Holland, E. C. Related Collections Tumor Biology Tumor Biology: Model Organisms and Imaging

Contributions of Human Tumor Xenografts to Anticancer Drug Development

Marlene and Stewart Greenebaum Cancer Center, and Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, Baltimore, Maryland

Requests for reprints: Edward A. Sausville, Marlene and Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Room S9D07, 22 South Greene Street, Baltimore, MD 21201. Phone: 410-328-7394; Fax: 410-328-6896; E-mail: esausville{at}umm.edu.

Abstract

Mouse models of cancer have consistently been used to qualify new anticancer drugs for study in human clinical trials. The most used models include transplantable murine tumors grown in syngeneic hosts and xenografts of human tumors grown in immunodeficient mice. For the latter systems, retrospective preclinical-clinical correlation studies are available, which suggest that improvements must be made to increase their value. Transgenic, knock-out, and knock-in mouse models and their intercrosses are more recent developments that mirror defined steps of human carcinogenesis. However, their value in predicting clinical results remains to date poorly defined. We take the position that properly used and interpreted human tumor xenografts grown in immunodeficient mice can be useful, although not absolutely predictive of behavior in the clinic, and continue to make contributions to critical clinical development choices. (cancer Res 2006;66(7):3351-4)

Departments of Cancer Biology and Genetics, Surgery (Neurosurgery) and Neurology, and Pediatrics Memorial Sloan-Kettering Cancer Center New York, New York.

This article has been cited by other articles:

				M. D. Ringel "Thyroid Cancer" Cell Line Misidentification: A Time for Proactive Change J. Clin. Endocrinol. Metab., November 1, 2008; 93(11): 4226 - 4227. [Full Text] [PDF]

				E. Oflazoglu, I. J. Stone, K. Gordon, C. G. Wood, E. A. Repasky, I. S. Grewal, C.-L. Law, and H.-P. Gerber Potent Anticarcinoma Activity of the Humanized Anti-CD70 Antibody h1F6 Conjugated to the Tubulin Inhibitor Auristatin via an Uncleavable Linker Clin. Cancer Res., October 1, 2008; 14(19): 6171 - 6180. [Abstract] [Full Text] [PDF]

				A. R. Shoemaker, M. J. Mitten, J. Adickes, S. Ackler, M. Refici, D. Ferguson, A. Oleksijew, J. M. O'Connor, B. Wang, D. J. Frost, et al. Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models Clin. Cancer Res., June 1, 2008; 14(11): 3268 - 3277. [Abstract] [Full Text] [PDF]

				P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study J. Clin. Oncol., May 10, 2008; 26(14): 2320 - 2326. [Abstract] [Full Text] [PDF]

				J. R. Tseng, K. W. Kang, M. Dandekar, S. Yaghoubi, J. H. Lee, J. G. Christensen, S. Muir, P. W. Vincent, N. R. Michaud, and S. S. Gambhir Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by 18F-FDG Small-Animal PET J. Nucl. Med., January 1, 2008; 49(1): 129 - 134. [Abstract] [Full Text] [PDF]

				O. Rixe and T. Fojo Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient? Clin. Cancer Res., December 15, 2007; 13(24): 7280 - 7287. [Abstract] [Full Text] [PDF]

				A. A. Kamat, W. M. Merritt, D. Coffey, Y. G. Lin, P. R. Patel, R. Broaddus, E. Nugent, L. Y. Han, C. N. Landen Jr., W. A. Spannuth, et al. Clinical and Biological Significance of Vascular Endothelial Growth Factor in Endometrial Cancer Clin. Cancer Res., December 15, 2007; 13(24): 7487 - 7495. [Abstract] [Full Text] [PDF]

				J. E. Talmadge, R. K. Singh, I. J. Fidler, and A. Raz Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer Am. J. Pathol., March 1, 2007; 170(3): 793 - 804. [Abstract] [Full Text] [PDF]

				C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, et al. Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis Cancer Res., January 1, 2007; 67(1): 32 - 40. [Abstract] [Full Text] [PDF]